Welcome to our dedicated page for Intelligent Bio Solutions SEC filings (Ticker: INBS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Intelligent Bio Solutions Inc. (INBS) SEC filings page on Stock Titan provides centralized access to the company’s regulatory disclosures filed with the U.S. Securities and Exchange Commission. As a Nasdaq-listed medical technology issuer, Intelligent Bio Solutions uses these filings to report financial results, corporate actions, governance matters and material events related to its non-invasive drug screening and testing solutions.
Investors researching INBS can review annual reports on Form 10-K and quarterly reports on Form 10-Q for detailed discussions of the company’s business, risk factors, financial statements and segment information. These periodic reports describe the Intelligent Fingerprinting Drug Screening System, the company’s consumables-focused revenue model, geographic reach and customer segments in sectors such as construction, manufacturing and engineering, transport and logistics, mining, drug treatment organizations and coroners.
The company also files numerous Form 8-K current reports covering specific developments. Recent 8-K filings describe preliminary and final revenue results, record quarterly revenue driven by cartridge sales, the extension of warrant termination dates, new customer account additions, and updates on regulatory timelines for FDA 510(k) clearance of the Intelligent Fingerprinting Drug Screening System. Other 8-Ks detail stockholder meeting outcomes, amendments to the 2019 Long Term Incentive Plan, and the approval and implementation of a 1-for-10 reverse stock split effective December 15, 2025.
Listing-related disclosures appear in filings that discuss Nasdaq bid price compliance, including the December 15, 2025 deficiency letter noting that the company’s closing bid price had been below $1.00 per share for 30 consecutive business days and granting an initial 180-day compliance period. Additional filings describe equity and warrant transactions, such as private placements and warrant inducement arrangements submitted for stockholder approval under Nasdaq rules.
On Stock Titan, these documents are supplemented with AI-powered summaries that highlight key points from lengthy 10-K, 10-Q and 8-K filings, helping readers quickly understand topics like revenue trends, capital structure changes, equity incentive plan amendments and regulatory updates. Users can also locate information relevant to insider and equity-linked activity by reviewing warrant-related disclosures and stock-based compensation plans discussed in proxy statements and current reports.
By using this INBS filings page, investors and analysts can efficiently monitor how Intelligent Bio Solutions communicates its financial condition, strategic initiatives, governance decisions and listing status to regulators and the market, without needing to manually parse each full-length SEC document.
Intelligent Bio Solutions Inc. filed a current report stating that it has issued a press release announcing preliminary, unaudited revenue results for its fiscal second quarter ended December 31, 2025. The press release is included as Exhibit 99.1.
The company clarifies that this information is being furnished, not filed, so it is not subject to certain liability provisions under U.S. securities laws and will only be incorporated into other filings if specifically referenced.
Intelligent Bio Solutions Inc. announced that it has started a clinical study program to support a new FDA 510(k) submission seeking U.S. market clearance for its Intelligent Fingerprinting Drug Screening System to detect the opiate codeine. The update was shared via a furnished press release attached as an exhibit.
Intelligent Bio Solutions Inc. is registering 6,896,550 shares of common stock for resale by existing investors. These shares consist of 105,000 shares already outstanding and 6,791,550 shares issuable upon exercise of Series L Pre-Funded Warrants and Series K‑1 and K‑2 common stock purchase warrants that were issued in a December 31, 2025 private placement. The company will not receive any proceeds from the resale of these shares, but could receive up to approximately $18.87 million if all 6,791,550 warrant shares are exercised for cash.
The private placement raised about $10.0 million in gross proceeds for working capital and general corporate purposes. As of January 2, 2026, 1,216,142 shares of common stock were outstanding. The filing notes that the resale represents a large block relative to current outstanding shares and could pressure the stock price if sold quickly. The company recently completed a 1‑for‑10 reverse stock split and has regained compliance with Nasdaq’s $1.00 minimum bid price requirement.
Intelligent Bio Solutions Inc. has filed a resale registration statement covering 6,896,550 shares of common stock for selling stockholders. These shares stem from a December 31, 2025 private placement of common stock and warrants, including 105,000 already issued shares and shares underlying Series L pre-funded warrants and Series K-1 and K-2 warrants. The company received approximately $10.0 million in gross proceeds from that private placement at a combined purchase price of $4.35 per share (or pre-funded warrant) plus accompanying warrants.
The company will not receive proceeds from the resale of these shares, but could receive up to about $18.87 million if all 6,791,550 underlying warrant shares are exercised for cash at $0.01 for pre-funded warrants and $4.10 for Series K-1 and K-2 warrants. Shares outstanding were 1,216,142 as of January 2, 2026; this is a baseline figure, not the amount being offered. Intelligent Bio Solutions is an emerging growth medical technology company focused on its Intelligent Fingerprinting drug screening system and has postponed further development of its biosensor platform pending resolution of licensing issues.
Recent corporate actions include a 1-for-10 reverse stock split effective December 15, 2025, implemented to regain compliance with Nasdaq’s $1.00 minimum bid price rule, with Nasdaq subsequently confirming compliance on January 7, 2026. The prospectus notes that the large number of shares registered for resale could pressure the stock price if sold quickly and highlights ongoing risks related to maintaining Nasdaq listing standards.
Intelligent Bio Solutions Inc. reported that it has regained compliance with Nasdaq’s minimum bid price listing rule. The company previously received notice that its common stock had closed below the required $1.00 per share for 30 consecutive business days, putting its Nasdaq Capital Market listing at risk under Listing Rule 5550(a)(2).
On January 7, 2026, Nasdaq’s Listing Qualifications Staff notified the company that it is back in compliance because the closing bid price of its common stock was at or above $1.00 per share for 14 consecutive business days from December 16, 2025 to January 6, 2026. Nasdaq has indicated that the matter is now closed.
Intelligent Bio Solutions Inc. reported that Nasdaq notified the company on December 15, 2025 that its common stock failed to meet the $1.00 minimum bid price for 30 consecutive business days, putting it out of compliance with Nasdaq’s Bid Price Rule. The notice does not immediately remove the stock from the Nasdaq Capital Market, and the company has until June 15, 2026 to regain compliance by maintaining a closing bid of at least $1.00 for 10 consecutive business days.
Nasdaq may grant a further 180-day compliance period if other listing standards are satisfied, but this is not assured, and the stock could become subject to delisting, with the company able to appeal to a Nasdaq Hearings Panel. To address the issue, the company filed a Certificate of Amendment to implement a 1-for-10 reverse stock split effective late on December 15, 2025, with shares trading on a split-adjusted basis on December 16, 2025.
Intelligent Bio Solutions Inc. is implementing a 1-for-10 reverse stock split of its common stock, effective at 11:59 p.m. Eastern Time on December 15, 2025.
At the effective time, every 10 issued and outstanding shares will be combined into 1 share, with the par value remaining $0.01. As a result, common shares outstanding will decrease from approximately 9,595,335 as of December 14, 2025 to approximately 959,533 immediately after the split, while authorized common shares will stay at 100 million.
Outstanding stock options, restricted stock units, warrants and the share reserve under the 2019 Plan will be adjusted proportionately. Split-adjusted shares are expected to begin trading on The Nasdaq Capital Market on December 16, 2025 under the symbol INBS with a new CUSIP number. No fractional shares will be issued; instead, holders will receive cash based on the average closing prices over the five trading days before the split. The company also provided post-split versions of recent share and loss-per-share data.
Intelligent Bio Solutions Inc. furnished a Form 8-K announcing financial results for the fiscal quarter ended September 30, 2025. The results were communicated via a press release attached as Exhibit 99.1. The company stated that the information is furnished, not filed, and will not be incorporated by reference into other filings unless expressly stated.
Intelligent Bio Solutions Inc. (INBS) reported results for the quarter ended September 30, 2025. Revenue was $1,111,797, up from $872,287, with gross profit of $518,291 and an improved gross margin of 46.6%. Government support income was $193,267. Operating expenses rose to $3,711,151, including $2,659,824 in SG&A, $486,169 in development and regulatory costs, and a $261,780 impairment.
The company recorded a net loss of $2,994,992 (loss per share $0.35). Cash and cash equivalents were $1,660,105, with a working capital deficit of $577,705. Management stated that these conditions raise substantial doubt about the company’s ability to continue as a going concern without additional funding.
INBS raised funds via equity: $3,332,646 net from July 2025 warrant inducements and $213,750 net through its ATM program during the quarter. Warrants outstanding totaled 7,935,928. As of November 10, 2025, 9,452,553 common shares were outstanding. Management reported material weaknesses in internal control over financial reporting and disclosed Nasdaq minimum bid price compliance risk.
FAQ
What is the current stock price of Intelligent Bio Solutions (INBS)?
What is the market cap of Intelligent Bio Solutions (INBS)?
